SCHEMBL7069376

SCHEMBL7069376

c1ccc(CNC2=NSc3cnccc3N2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
IDO1 P14902 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
EGFR P00533 2/20 0.42
KDM4C Q9H3R0 2/20 0.41
KDM4E B2RXH2 1/20 0.41
KDM6B O15054 1/20 0.41
KDM4A O75164 1/20 0.41
KDM4D Q6B0I6 1/20 0.41
LTA4H P09960 1/20 0.40
KCNH3 Q9ULD8 1/20 0.38
FABP1 P07148 1/20 0.36
FABP6 P51161 1/20 0.36
MAPKAPK2 P49137 1/20 0.35
CYP1A2 P05177 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8717638 0.81 IDO1 (0.40) GAAMAPTIDO1L3MBTL1ALDH1A1
SCHEMBL8720054 0.79 IDO1 (0.42) GAAMAPTIDO1L3MBTL1ALDH1A1
SCHEMBL8585966 0.77 MMP3 (0.37) ALDH1A1FABP1FABP6HSD17B10
SCHEMBL7069919 0.77 CA12 (0.38) GAAMAPTIDO1L3MBTL1ALDH1A1
SCHEMBL8720094 0.77 L3MBTL1 (0.38) GAAMAPTIDO1L3MBTL1
SCHEMBL16974876 0.75 ALDH1A1 (0.50) GAAMAPTL3MBTL1ALDH1A1MEN1
SCHEMBL16974890 0.75 KMT2A (0.41) MAPTALDH1A1MEN1HPGDKMT2A
SCHEMBL7067988 0.75 GAA (0.44) GAAMAPTIDO1L3MBTL1
SCHEMBL8717908 0.75 GAA (0.36) GAAMAPTIDO1L3MBTL1ALDH1A1
SCHEMBL8720104 0.74 GAA (0.42) GAAMAPTIDO1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003105896-A1 COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND NOVO NORDISK A/S (DK) 2003-12-24 WO claimed
WO-2003045954-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 WO claimed
WO-2003045955-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 WO claimed
WO-2002000222-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER NOVO NORDISK A/S (DK) 2002-01-03 WO claimed
WO-2002000223-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION NOVO NORDISK A/S (DK) 2002-01-03 WO claimed
EP-0877748-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1998-11-18 EP claimed
WO-1997026264-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1997-07-24 WO claimed
WO-2003105896-A1 COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND NOVO NORDISK A/S (DK) 2003-12-24 WO disclosed
WO-2002000222-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER NOVO NORDISK A/S (DK) 2002-01-03 WO disclosed
WO-2002000223-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION NOVO NORDISK A/S (DK) 2002-01-03 WO disclosed
EP-0877748-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1998-11-18 EP disclosed
WO-1997026264-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1997-07-24 WO disclosed